BR0215312A - Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto - Google Patents

Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto

Info

Publication number
BR0215312A
BR0215312A BR0215312-2A BR0215312A BR0215312A BR 0215312 A BR0215312 A BR 0215312A BR 0215312 A BR0215312 A BR 0215312A BR 0215312 A BR0215312 A BR 0215312A
Authority
BR
Brazil
Prior art keywords
compound
aurora kinase
preparing
pharmaceutical composition
inhibiting aurora
Prior art date
Application number
BR0215312-2A
Other languages
English (en)
Other versions
BRPI0215312B8 (pt
BRPI0215312B1 (pt
Inventor
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0215312A publication Critical patent/BR0215312A/pt
Publication of BRPI0215312B1 publication Critical patent/BRPI0215312B1/pt
Publication of BRPI0215312B8 publication Critical patent/BRPI0215312B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

"USO DE UM COMPOSTO, MéTODO PARA INIBIR A AURORA QUINASE EM UM ANIMAL DE SANGUE QUENTE, COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A invenção fornece derivados de quinazolina de fórmula (I): na preparação de um medicamento para uso na inibição da Aurora quinase e, também, novos derivados de quinazolina, processos para sua preparação, composições farmacêuticas contendo-os, e seu uso em terapia.
BRPI0215312A 2001-12-24 2002-12-20 composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto BRPI0215312B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01403357.5 2001-12-24
EP01403357 2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en) 2001-12-24 2002-12-20 Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (3)

Publication Number Publication Date
BR0215312A true BR0215312A (pt) 2004-12-07
BRPI0215312B1 BRPI0215312B1 (pt) 2018-03-27
BRPI0215312B8 BRPI0215312B8 (pt) 2021-05-25

Family

ID=8183051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215312A BRPI0215312B8 (pt) 2001-12-24 2002-12-20 composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto

Country Status (32)

Country Link
US (2) US7402585B2 (pt)
EP (1) EP1463506B1 (pt)
JP (1) JP4498741B2 (pt)
KR (1) KR101029281B1 (pt)
CN (1) CN100491372C (pt)
AR (1) AR038052A1 (pt)
AT (1) ATE446093T1 (pt)
AU (1) AU2002353196B2 (pt)
BR (1) BRPI0215312B8 (pt)
CA (1) CA2471577C (pt)
CY (1) CY1109681T1 (pt)
DE (1) DE60234125D1 (pt)
DK (1) DK1463506T3 (pt)
ES (1) ES2333702T3 (pt)
HK (1) HK1076598A1 (pt)
HU (1) HU229477B1 (pt)
IL (1) IL162541A0 (pt)
IS (1) IS2758B (pt)
MX (1) MXPA04006260A (pt)
MY (1) MY141739A (pt)
NO (1) NO328159B1 (pt)
NZ (1) NZ533440A (pt)
PL (1) PL211694B1 (pt)
PT (1) PT1463506E (pt)
RU (1) RU2323215C2 (pt)
SA (1) SA03230531B1 (pt)
SI (1) SI1463506T1 (pt)
TW (1) TWI335818B (pt)
UA (1) UA82058C2 (pt)
UY (1) UY27604A1 (pt)
WO (1) WO2003055491A1 (pt)
ZA (1) ZA200404923B (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
CA2522079A1 (en) 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
PT1660090E (pt) * 2003-08-14 2013-01-11 Array Biopharma Inc Análogos de quinazolina como inibidores de tirosina-cinases recetoras
DK2210607T3 (da) 2003-09-26 2011-12-12 Exelixis Inc N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
JP4845736B2 (ja) * 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
EP1768984B1 (en) * 2004-07-16 2010-10-20 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
EP1778669A2 (en) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
TW200624431A (en) * 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
ES2545382T3 (es) 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
AU2006272876A1 (en) 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
WO2007041358A2 (en) * 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
JP2009528336A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
AU2007229063A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
US20070287706A1 (en) * 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
US20100022404A1 (en) 2006-10-05 2010-01-28 Shinichi Hasako Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
JP5516397B2 (ja) 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法
EP2166849A4 (en) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc SUBSTITUTED PYRAZOL COMPOUNDS
US7968536B2 (en) 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
EP2262796A1 (en) 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
WO2010083414A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
KR101699991B1 (ko) * 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465842A1 (de) * 2010-12-17 2012-06-20 Sika Technology AG Amine mit sekundären aliphatischen Aminogruppen
KR101940340B1 (ko) 2011-03-04 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 아미노-퀴놀린
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JP6134376B2 (ja) 2012-03-16 2017-05-24 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
KR20150118152A (ko) * 2013-02-21 2015-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 키나제 억제제로서의 퀴나졸린
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
MY191804A (en) 2013-09-16 2022-07-15 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
JP6527513B2 (ja) 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
LT3122358T (lt) 2014-03-26 2021-04-12 Astex Therapeutics Ltd. Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
MX2017008526A (es) 2014-12-23 2017-10-25 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol quinasa.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
CN108026095B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 新化合物
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
KR100860295B1 (ko) 1998-10-08 2008-09-25 아스트라제네카 아베 퀴나졸린 유도체
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
JP4870304B2 (ja) 1999-09-21 2012-02-08 アストラゼネカ アクチボラグ キナゾリン誘導体およびそれらの医薬品としての使用
GB0006864D0 (en) * 2000-03-21 2000-05-10 Smithkline Beecham Plc New use
PL360439A1 (en) * 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7105425B1 (en) * 2002-05-16 2006-09-12 Advanced Micro Devices, Inc. Single electron devices formed by laser thermal annealing
SI1578755T1 (sl) * 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
US20060135541A1 (en) * 2003-06-02 2006-06-22 Astrazeneca Ab (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
EP1802608A1 (en) * 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
WO2006129064A1 (en) * 2005-05-28 2006-12-07 Astrazeneca Ab Quinazolines and their use as aurora kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
EP2231281A2 (en) * 2007-12-12 2010-09-29 AstraZeneca AB Combination comprising a mek inhibitor and an aurora kinase inhibitor

Also Published As

Publication number Publication date
PT1463506E (pt) 2009-12-10
US7402585B2 (en) 2008-07-22
AU2002353196A1 (en) 2003-07-15
ES2333702T3 (es) 2010-02-26
NZ533440A (en) 2006-08-31
MXPA04006260A (es) 2005-03-31
PL371253A1 (en) 2005-06-13
BRPI0215312B8 (pt) 2021-05-25
ZA200404923B (en) 2005-11-30
PL211694B1 (pl) 2012-06-29
RU2004122926A (ru) 2005-07-10
US20050070561A1 (en) 2005-03-31
TWI335818B (en) 2011-01-11
RU2323215C2 (ru) 2008-04-27
CN100491372C (zh) 2009-05-27
UY27604A1 (es) 2003-07-31
KR101029281B1 (ko) 2011-04-18
CN1620296A (zh) 2005-05-25
TW200410697A (en) 2004-07-01
EP1463506B1 (en) 2009-10-21
CA2471577A1 (en) 2003-07-10
BRPI0215312B1 (pt) 2018-03-27
AU2002353196B2 (en) 2008-01-17
DE60234125D1 (de) 2009-12-03
HUP0402454A2 (hu) 2005-03-29
HK1076598A1 (en) 2006-01-20
SA03230531B1 (ar) 2008-09-08
DK1463506T3 (da) 2010-01-11
IS7328A (is) 2004-06-21
NO20043158L (no) 2004-09-16
AR038052A1 (es) 2004-12-22
JP2005525307A (ja) 2005-08-25
ATE446093T1 (de) 2009-11-15
HUP0402454A3 (en) 2009-08-28
MY141739A (en) 2010-06-15
EP1463506A1 (en) 2004-10-06
SA03230531A (ar) 2005-12-03
KR20040066929A (ko) 2004-07-27
CY1109681T1 (el) 2014-08-13
IS2758B (is) 2011-10-15
UA82058C2 (uk) 2008-03-11
JP4498741B2 (ja) 2010-07-07
IL162541A0 (en) 2005-11-20
WO2003055491A1 (en) 2003-07-10
HU229477B1 (en) 2014-01-28
CA2471577C (en) 2011-08-02
NO328159B1 (no) 2009-12-21
SI1463506T1 (sl) 2010-01-29
US20090215770A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0213843A (pt) Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
BRPI0414772A (pt) derivado de quinazolina, composto, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0312464A (pt) Inibidores de tirosina quinases
BR0213842A (pt) Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável
BR0308670A (pt) Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de seu sal, método para produzir um efeito anti-proliferativo em um animal de sangue quente em necessidade de tal tratamento, e, composto ou um sal deste.
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0317717B8 (pt) composto, composição farmacêutica, e uso de um composto
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
ATE316083T1 (de) Adamantanderivate
BR0108678A (pt) Novos compostos
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR9814375A (pt) Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BRPI0414735A (pt) derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
BRPI0516093A (pt) derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/517

Ipc: A61K 31/517 (2011.01), A61P 35/00 (2011.01), A61P

Free format text: PARA: INT. CL. A61K 31/517; A61P 35/00, 43/00

Ipc: A61K 31/517 (2011.01), A61P 35/00 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/12/2022